Tradestie Institutional Equity Comparison Engine
CNTX vs SGMT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SGMT Overall Edge
SGMT Captures Institutional Edge (3โ0 Pillars ยท 4โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Sagimet Biosciences Inc. Series A Common Stock (SGMT) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CNTX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SGMT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CNTX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SGMT sits in CONSOLIDATION (82nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CNTX N/M vs SGMT N/M Fwd P/E
Growth & Margin Winner
SGMT
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
SGMT
1Y -86.3% vs +15.7% ยท 52W Pos 0% vs 66%
Options & Structure Winner
SGMT
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (82nd %ile IV)
CNTX
NASDAQ
Context Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$0.16
-5.1% 1D
Market Cap
$15.5M
1M Return
-32.09%
1Y Return
-86.32%
Forward P/E
N/M
Unified AI Score
46.6 / 100
HOLD
Tech 33.0
Fund 58.0
Flow 50.0
Mom 68.9
SGMT
NASDAQ
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.08
-5.61% 1D
Market Cap
$692.0M
1M Return
-8.74%
1Y Return
+15.67%
Forward P/E
N/M
Unified AI Score
44.6 / 100
HOLD
Tech 22.0
Fund 48.0
Flow 70.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CNTX -86.32%
SGMT +15.67%
Spread: +101.99 pp (SGMT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CNTX TTM Op. Margin: 0.0%
SGMT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNTX vs SGMT. Trailing 12-month operating profitability (CNTX 0.0% vs SGMT 0.0%) and valuation multiples (CNTX N/M vs SGMT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CNTX | SGMT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.5M | $692.0M | Larger Scale | SGMT |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -84.3% | -29.5% | Higher ROE | SGMT |
| 52-Week Range Position Momentum | 0% ($0โ$4) | 66% ($4โ$11) | Stronger Trend | SGMT |
| Beta / 30D Volatility Risk Regime | 0.82ฮฒ ยท 98% Vol | 2.04ฮฒ ยท 80% Vol | Lower Realized Risk | SGMT |
| Unified Institutional Score Composite Signal | 46.6 / 100 (HOLD) | 44.6 / 100 (HOLD) | Higher Composite | CNTX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CNTX vs SGMT Buy Guide
CNTX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SGMT
CONSOLIDATION
144d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
82nd %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CNTX nor SGMT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.